Although more work is needed to define its regulation, our data confirm NLRP3 as a therapeutic target in patients with MPN, particularly those in whom excessive platelet production is of primary concern, such as in ET and prefibrotic PMF. This evidence concerns the gene NLRP3 and myeloproliferative disorder.